Lenalidomide is an immunomodulatory agent with therapeutic activity in chronic lymphocytic leukemia (CLL). The CLL Research Consortium initiated a phase 2 study to evaluate this combination in treatment-naive patients.

Lenalidomide was initiated at 2.5 mg/day and was escalated based on treatment tolerability to a maximum of 10 mg/day, for 21 days/cycle, for a maximum of seven cycles.

READ FULL ARTICLE Curated publisher From Ascopubs